Serum CXCL10 levels and neuromuscular manifestations in patients with autoimmune thyroid diseases
Authors:
- 9 February 2011
- journal article
- Published by Taylor & Francis in Autoimmunity
- Vol. 44 (6) , 496-503
Abstract
Serum C-X-C motif chemokine 10 (CXCL10) levels have been shown to be elevated in autoimmune thyroid diseases (AITD). This study sought to determine whether newly diagnosed AITD patients with neuromuscular findings had higher levels of CXCL10 than those without neuromuscular manifestations. A total of 80 patients were recruited to the study, which included treatment-naive hypothyroid Hashimoto's thyroiditis (n = 19) and hyperthyroid Graves' disease (GD; n = 21), euthyroid thyroid autoantibody-positive (n = 20) and -negative (n = 20) patients. All patients underwent a thorough sensorimotor and neuromuscular examination. Serum samples were kept in - 20°C for further CXCL10 measurements with ELISA. There was a significant difference with regard to serum CXCL10 levels only between GD and euthyroid thyroid autoantibody-negative patient groups [187(12-418) vs. 37.5(2-542) pg/ml, p < 0.05]. However, a comparison of newly diagnosed AITD patients with and without neuromuscular manifestations in terms of serum CXCL10 levels yielded no significant difference. When a correlation of existence of a neuromuscular manifestation and serum CXCL10 levels was evaluated, a significantly positive correlation was noted between carpal tunnel syndrome (CTS) and serum CXCL10 levels [207 (95-748) pg/ml in CTS-positive vs. 117 (2-977) pg/ml in CTS-negative patients, p < 0.05]. In this study, from a number of neuromuscular manifestations, only the existence of CTS correlated with significantly higher CXCL10 levels in the whole study group. Further studies with larger numbers of patients with autoimmune-based hyper- and hypothyroidism may better clarify the hypothesis regarding a relationship between serum CXCL10 levels and neuromuscular manifestations of AITD.Keywords
This publication has 29 references indexed in Scilit:
- Monokine Induced by Interferon γ (IFNγ) (CXCL9) and IFNγ Inducible T-Cell α-Chemoattractant (CXCL11) Involvement in Graves’ Disease and Ophthalmopathy: Modulation by Peroxisome Proliferator-Activated Receptor-γ AgonistsThe Journal of Clinical Endocrinology & Metabolism, 2009
- Chemokines and Autoimmune Thyroid DiseasesHormone and Metabolic Research, 2008
- Role of Chemokines in Endocrine Autoimmune DiseasesEndocrine Reviews, 2007
- Iodine-131 Given for Therapeutic Purposes Modulates Differently Interferon-γ-Inducible α-Chemokine CXCL10 Serum Levels in Patients with Active Graves’ Disease or Toxic Nodular GoiterThe Journal of Clinical Endocrinology & Metabolism, 2007
- Serum levels of the interferon-γ-inducible α chemokine CXCL10 in patients with active Graves' disease, and modulation by methimazole therapy and thyroidectomyBritish Journal of Surgery, 2006
- Increased serum CXCL10 in Graves’ disease or autoimmune thyroiditis is not associated with hyper- or hypothyroidism per se, but is specifically sustained by the autoimmune, inflammatory processEuropean Journal of Endocrinology, 2006
- Interferon-γ-Inducible α-Chemokine CXCL10 Involvement in Graves’ Ophthalmopathy: Modulation by Peroxisome Proliferator-Activated Receptor-γ AgonistsThe Journal of Clinical Endocrinology & Metabolism, 2006
- High Levels of Circulating CXC Chemokine Ligand 10 Are Associated with Chronic Autoimmune Thyroiditis and HypothyroidismThe Journal of Clinical Endocrinology & Metabolism, 2004
- ?to: Nicoletti F, Conget L, Di Mauro M et al. (2002) Serum concentrations of the interferon-?-inducible chemokine IP-10/CXCL10 are augmented in both newly-diagnosed Type I diabetes mellitus patients and subjects at risk of developing the disease. Diabetologia 45:1107?1110Diabetologia, 2003
- Expression of IP-10/CXCL10 and MIG/CXCL9 in the Thyroid and Increased Levels of IP-10/CXCL10 in the Serum of Patients with Recent-Onset Graves' DiseaseThe American Journal of Pathology, 2002